The IGR-CaP1 Xenograft Model Recapitulates Mixed Osteolytic/Blastic Bone Lesions Observed in Metastatic Prostate Cancer

Archive ouverte

Al Nakouzi, Nader | Bawa, Olivia | Le Pape, Alain | Lerondel, Stéphanie | Gaudin, Catherine | Opolon, Paule | Gonin, Patrick | Fizazi, Karim | Chauchereau, Anne

Edité par CCSD ; Elsevier -

International audience. Bone metastases have a devastating impact on quality of life and bone pain in patients with prostate cancer and decrease survival. Animal models are important tools in investigating the pathogenesis of the disease and in developing treatment strategies for bone metastases, but few animal models recapitulate spontaneous clinical bone metastatic spread. In the present study, IGR-CaP1, a new cell line derived from primary prostate cancer, was stably transduced with a luciferase-expressing viral vector to monitor tumor growth in mice using bioluminescence imaging. The IGR-CaP1 tumors grew when subcutaneously injected or when orthotopically implanted, reconstituted the prostate adenocarcinoma with glandular acini-like structures, and could disseminate to the liver and lung. Bone lesions were detected using bioluminescence imaging after direct intratibial or intracardiac injections. Anatomic bone structure assessed using high-resolution computed tomographic scans showed both lytic and osteoblastic lesions. Technetium Tc 99m methylene diphosphonate micro single-photon emission computed tomography confirmed the mixed nature of the lesions and the intensive bone remodeling. We also identified an expression signature for responsiveness of IGR-CaP1 cells to the bone microenvironment, namely expression of CXCR4, MMP-9, Runx2, osteopontin, osteoprotegerin, ADAMTS14, FGFBP2, and HBB. The IGR-CaP1 cell line is a unique model derived from a primary tumor, which can reconstitute human prostate adenocarcinoma in animals and generate experimental bone metastases, providing a novel means for understanding the mechanisms of bone metastasis progression and allowing preclinical testing of new therapies.

Suggestions

Du même auteur

Establishment of a new preclinical human prostate cancer model and identification of docetaxel-resistance biomarker. Etablissement d'un nouveau modèle pérclinique de cancer de la prostate et identification de biomarqueurs de résistance au docetaxel

Archive ouverte | Al Nakouzi, Nader | CCSD

One of the major hindrances in the study of the biology of prostate cancer is the limited number of laboratory models. Most of these models have been obtained from prostate tumor metastases or have been artificially established in...

Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer

Archive ouverte | Al Nakouzi, Nader | CCSD

International audience. Docetaxel is used as a standard treatment in patients with metastatic castration-resistant prostate cancer. However, a large subset of patients develops resistance. Understanding resistance m...

Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer

Archive ouverte | Chauchereau, Anne | CCSD

International audience. Deciphering molecular pathways involved in the early steps of prostate oncogenesis requires both in vitro and in vivo models derived from human primary tumors. However the few recognized mode...

Chargement des enrichissements...